1187595-90-9

Basic information

• Product Name: (4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
• Synonyms: (4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
• CAS NO: 1187595-90-9
• Molecular Formula: C₂₂H₂₇N₇O₄S
• Molecular Weight: 485.55928
• Mol File: 1187595-90-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate(1187595-90-9)
• EPA Substance Registry System: (4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate(1187595-90-9)

Safety Data

• Hazardous Substances Data: 1187595-90-9(Hazardous Substances Data)

Usage

General Description

The chemical compound "(4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate" is a complex molecule with a pyrrolopyrimidine core structure. It contains a cyanomethyl group, an ethylsulfonyl group, and a pivalate ester moiety. (4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate may have potential pharmaceutical applications due to its structural features, such as its pyrazole and azetidine substructures. The presence of the cyanomethyl and ethylsulfonyl groups suggests potential reactivity and functionality in biological systems, and the pivalate ester may enhance the compound's stability and bioavailability. Further research and testing are likely necessary to fully understand the properties and potential uses of this chemical.

Upstream product

• 1146629-77-7 [4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl 2,2-dimethylpropanoate 
• 1153949-11-1 3-(cyanomethylene)azetidine-1-carboxylic acid tert-butyl ester 
• 3724-43-4 Vilsmeier reagent 
• 1187595-85-2 2-[1-(ethanesulfonyl)azetidin-3-ylidene]acetonitrile 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1146629-75-5 (4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl 2,2-dimethylpropanoate 
• 18997-19-8 Chloromethyl pivalate 
• 55052-28-3 4-chloro-7-azaindole 
• 1146629-76-6 [4-[1-(1-ethoxyethyl)-1H-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate 

Downstream Products

• 1187594-09-7 Baricitinib 

Relevant articles and documents

Preparation of baricitinib and derivative thereof

The invention relates to synthesis of baricitinib and a derivative thereof. Specifically, (4-(1, 3-dioxolane-2-yl)-7-substituted-7H-pyrrolo [2, 3-d] pyrimidine reacts with 2-(1-(ethylsulfonyl)-3-hydrazino azetidin-3-yl) acetonitrile and (chloromethylene) dimethyl ammonium chloride in the presence of a solvent to obtain a compound 2-(1-(ethylsulfonyl)-3-(4-(7-substituted-7H-pyrrolo [2, 3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile.

Synthesis and Characterization of Compounds Potentially Related to the Janus Kinase Inhibitor Baricitinib

Nine compounds potentially related to the Janus kinase inhibitor Baricitinib have been identified, synthesized by conventional methods, and characterized by IR, 1H and 13C NMR, and mass spectral data.

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.